DNA Script to Team up With Moderna for Vaccine and Therapeutic Manufacturing for DARPA

News
Article

With a $5 million grant from DARPA, DNA Script and Moderna will develop a prototype for rapid mobile manufacturing of vaccines and therapeutics as part of the DARPA’s Nucleic Acids On-Demand World-Wide program.

DNA Script, a disruptive DNA synthesis company based in France, announced on April 27, 2021 that it has entered into a partnership with Moderna to develop a prototype for rapid mobile manufacturing of vaccines and therapeutics as part of the US Defense Advanced Research Projects Agency's (DARPA) Nucleic Acids On-Demand World-Wide (NOW) program.

With a $5 million grant from DARPA, the collaboration will involve the use of DNA Script's novel enzymatic synthesis platform to rapidly generate high-fidelity nucleic acids without the use of chemical solvents to power Moderna's manufacturing technology for the production of messenger RNA therapeutics and vaccines, DNA Script said in a company press release.

"We are thrilled to collaborate with Moderna and DARPA on this important initiative to create an innovative biotechnological approach to rapidly detect, characterize, and mitigate threats from newly emerging or engineered pathogens," said Thomas Ybert, CEO of DNA Script, in the press release. "We believe that our fast, efficient, and intuitive Syntax nucleic acid printer, underpinned by our proprietary enzymatic DNA synthesis technology, has the potential to help prevent future pandemics. We're proud to have been selected by both partners receiving awards under this DARPA NOW initiative."

Source: DNA Script

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content